SCHEMBL6474055

SCHEMBL6474055

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2ccc(-c3cccs3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 3/20 0.44
GRIA4 P48058 9/20 0.44
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
PSMB5 P28074 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRIA1 P42261 1/20 0.38
GRIA3 P42263 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP2 P08253 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474497 0.94 GRIA4 (0.43) GRIA2GRIA4PPARGPPARAPSMB5
SCHEMBL6482318 0.85 GRIA4 (0.53) GRIA2GRIA4MAPTGRIA1GRIA3
SCHEMBL6474062 0.85 PSMB5 (0.43) GRIA2GRIA4PPARGPPARAPSMB5
SCHEMBL6475291 0.83 GRIA4 (0.62) GRIA2GRIA4MAPTGRIA1GRIA3
SCHEMBL6482156 0.80 MTNR1A (0.52) GRIA2GRIA4GRIA1GRIA3MMP2
SCHEMBL6474389 0.80 GRIA4 (0.62) GRIA2GRIA4PPARGPPARAMEN1
SCHEMBL6474502 0.80 PSMB5 (0.42) GRIA4PPARGPPARAPSMB5KDM4E
SCHEMBL6475864 0.80 GRIA4 (0.67) GRIA2GRIA4GRIA1GRIA3
SCHEMBL6528249 0.80 GRIA4 (0.67) GRIA2GRIA4GRIA1GRIA3
SCHEMBL5877990 0.80 GRIA4 (0.66) GRIA2GRIA4GRIA1GRIA3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA2 3/4885GRIA4 6/4885PPARG 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.